Clinical Social Workers in Statesboro, GA Accepting Medicare

9 Clinical Social Workers found. Showing 1 - 9

Mr. Stephen R. Fishack, M.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 106 Oak St Ste A, Statesboro, GA 30458 Phone: 912-678-3098    Fax: 912-764-5661

Amy Payne Clifton, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 204 S Main St, Statesboro, GA 30458 Phone: 912-662-6501

April Michelle Schueths, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 114 N College St, Statesboro, GA 30458 Phone: 912-266-8830

Ms. Stephanie Lupita Spencer, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 337 S Walnut St, Statesboro, GA 30458 Phone: 912-571-0567

Gaynell Denise Hill Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 207 Lee Dr, Statesboro, GA 30461 Phone: 912-536-1643

Elyse Bridget Casher, MSW, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 124 Savannah Ave Ste 1c, Statesboro, GA 30458 Phone: 912-452-2335

Ashley Kathryn Hand, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 100 Brampton Ave, Statesboro, GA 30458 Phone: 912-225-3750

Kim Hulsey, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 19 Lester Rd, Statesboro, GA 30458 Phone: 912-662-6501    Fax: 912-681-1012

Delores Deanne Liston, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 112 N College St, Statesboro, GA 30458 Phone: 912-536-1164

News Archive

Patents listed in FDA's Orange Book for Eli Lilly's Evista invalidated

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version. The court found these patents to be invalid for lack of written description.

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

Researchers reveal link between intensive instrument playing and movement disorders

A musician takes up his/her violin and starts to play, but rather than gripping the strings, the fingers seize up—and this happens every time he/she takes up the instrument. Such a movement disorder—the so-called focal dystonia— is a dramatic disease for those affected, which has thus far barely been studied.

BREAKYL drug receives European approval

BioDelivery Sciences International, Inc. and Meda today announced approval of BEMA Fentanyl in Europe via the Decentralized Procedure, with Germany acting as Reference Member State.

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML).

Read more Medical News

› Verified 4 days ago